Barclays PLC Has $3.48 Million Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)

Barclays PLC lifted its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 140.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 60,014 shares of the company's stock after purchasing an additional 35,022 shares during the period. Barclays PLC owned about 0.15% of Keros Therapeutics worth $3,484,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in KROS. Point72 Asset Management L.P. raised its position in shares of Keros Therapeutics by 155.9% during the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company's stock worth $55,025,000 after purchasing an additional 577,220 shares during the period. Alkeon Capital Management LLC raised its holdings in Keros Therapeutics by 18.7% during the 3rd quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company's stock worth $110,194,000 after buying an additional 298,694 shares during the period. Parkman Healthcare Partners LLC lifted its stake in Keros Therapeutics by 112.3% during the third quarter. Parkman Healthcare Partners LLC now owns 421,782 shares of the company's stock valued at $24,493,000 after buying an additional 223,155 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of Keros Therapeutics by 814.6% in the third quarter. Assenagon Asset Management S.A. now owns 223,704 shares of the company's stock worth $12,990,000 after buying an additional 199,245 shares during the period. Finally, FMR LLC increased its position in shares of Keros Therapeutics by 3.8% in the third quarter. FMR LLC now owns 4,899,134 shares of the company's stock worth $284,493,000 after acquiring an additional 179,374 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Stock Performance

Shares of NASDAQ KROS traded down $0.41 during trading hours on Tuesday, hitting $16.71. The stock had a trading volume of 378,972 shares, compared to its average volume of 488,891. The firm's 50-day moving average price is $54.10 and its two-hundred day moving average price is $51.40. Keros Therapeutics, Inc. has a 52 week low of $15.67 and a 52 week high of $73.00. The company has a market capitalization of $676.87 million, a P/E ratio of -3.21 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The business had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm's quarterly revenue was up 4750.0% on a year-over-year basis. During the same period last year, the company earned ($1.33) earnings per share. As a group, analysts expect that Keros Therapeutics, Inc. will post -5.26 EPS for the current fiscal year.

Analysts Set New Price Targets

KROS has been the subject of several research analyst reports. Guggenheim downgraded shares of Keros Therapeutics from a "buy" rating to a "neutral" rating in a research report on Monday, December 16th. Oppenheimer reduced their target price on Keros Therapeutics from $102.00 to $63.00 and set an "outperform" rating for the company in a report on Monday, December 16th. TD Cowen downgraded Keros Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday, December 12th. Cantor Fitzgerald reissued an "overweight" rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. Finally, HC Wainwright decreased their price objective on Keros Therapeutics from $100.00 to $47.00 and set a "buy" rating for the company in a research report on Friday, December 13th. Four investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $75.00.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.